<DOC>
	<DOCNO>NCT02646852</DOCNO>
	<brief_summary>This Phase I , two-stage , open-label , single-arm , dose escalation study DFP-13318 intravenous infusion administer patient refractory relapse solid tumor . This study explore two different dose schedules- every 3 week ( q3w ) every 2 week ( q2w ) - Stage 1 Stage 2 , respectively .</brief_summary>
	<brief_title>A Phase I Study DFP-13318 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>DFP-11318 investigational drug product demonstrate reasonable antitumor activity preclinical colorectal , gastric lung tumor model animal . This first human trial determine maximum , safest dose DFP-11318 IV administer patient either every 3 week every 2 week .</detailed_description>
	<criteria>Patients must histologically ( cytologically ) confirm diagnosis solid tumor , refractory standard therapy disease conventional systemic therapy reliably effective effective therapy available . Aged ≥ 18 year . ECOG Performance Status 0 1 . Adequate clinical laboratory value define : absolute neutrophil count ≥ 1.5x10^9/L platelet ≥ 100x10^9/L hemoglobin ≥ 9.0 g/dL ( transfusion permissible ) plasma creatinine ≤ 1.5 x upper limit normal ( ULN ) institution calculate clearance ≥ 60 mL/min ( CockcroftGault formula ) bilirubin ≤ 1.5 x ULN alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 x ULN ( &lt; 5 x ULN document hepatic metastasis ) Serum sodium , potassium , magnesium calcium within normal limit institution ( supplement may give correct value ) Absence uncontrolled intercurrent illness , include uncontrolled infection , cardiac condition , organ dysfunction . Patients may measurable nonmeasurable disease define RECIST 1.1 . Signed informed consent prior start study specific procedure . Women childbearing potential must negative serum urine pregnancy test . Male female patient must agree use acceptable contraceptive method duration study least one month last drug administration . Patients exclude receive previous chemotherapy , immunotherapy , radiotherapy investigational therapy within 4 week ( 6 week nitrosoureas mitomycin C ) 5 halflives target therapy prior study entry . Have recover adverse event ( must grade ≤1 ) due agent administer 4 week earlier . Known hypersensitivity study drug component . Extensive prior radiotherapy , 30 % bone marrow reserve , prior bone marrow/stem cell transplantation . Any concomitant condition opinion investigator could compromise objective study patient 's compliance . Pregnant lactating individual . Current malignancies another type , exception adequately treat situ cervical cancer basal cell skin cancer malignancy evidence disease 2 year . Known history HIV , HBV HCV infection . Documented known bleeding disorder . Requirement anticoagulation treatment increase INR aPTT normal range ( low dose DVT line prophylaxis allow ) . Clinically evident CNS metastases leptomeningeal disease control prior surgery radiotherapy ; history seizure disorder control antiseizure medication time enrollment . Patients primary CNS malignancy exclude . Patients significant cardiovascular disease condition , include : Myocardial infarction within 6 month study entry NYHA Class III IV heart failure Uncontrolled dysrhythmias poorly control angina . History serious ventricular arrhythmia ( VT VF , ≥ 3 beat row ) and/or risk factor ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Baseline prolongation QT/QTc interval ( repeat demonstration QTc ≥ 450 msec men 470 msec woman ) , LVEF ≤ 40 % MUGA ECHO . History clinically significant gastrointestinal bleeding , colitis , gastrointestinal perforation . Patients require treatment UGT1A1 inhibitor period investigational treatment DFP13318 . Patients know Gilbert 's syndrome reduce UGT1A1 activity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>